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1. Introduction1
Heart failure (HF) is a condition in which the heart can-
not pump enough blood to meet the body’s need. It is also 
under group of pulmonary circulation and systemic con-
gestion. The clinical manifestations of the syndrome were 
the lack of blood perfusion to tissue and organ of the body. 
Heart diseases are composed of various structural or func-
tional of heart problems where leading to ventricular fill-
ing and injection of blood is low, as result cardiac output 
cannot meet the body’s metabolic demands. When com-
bined with atrial fibrillation in patients with heart failure, 
it can make the hemodynamic disorder worst. It is serious-
ly affect the physical and mental health of patients, so that 
the mortality rate is greatly increased. In recent years, with 
the improvement of living standards, and the ageing of the 
population aggravated, the elderly patients with chronic 
atrial fibrillation and heart failure incidence is increasing 
year by year and both reinforce each other with mutual 
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restriction [1]. Therefore, the purpose of this study is to 
explore the clinical treatment of chronic atrial fibrillation 
and heart failure in elderly patients.
2. Materials and methods
2.1. Clinical data
A total of 120 cases of chronic atrial fibrillation and heart 
failure in elderly patients in our hospital were admitted 
from March 2011 to March 2014 and was selected as the 
subject of study. Generally, some symptoms experienced 
by patients are as multiple palpitations, shortness of breath, 
and increased dyspnea, cannot lie on the back, orthopnea, 
fatigue, dizziness and amaurosis, edema, cough, expecto-
ration, hemoptysis, less urine, and other symptoms. From 
the 120 of patients with chronic atrial fibrillation and heart 
failure were randomly divided into control group and 
treatment group with 60 patients in each group. There were 
33 male and 27 female, aged 60−85 (68.7 + 8.9) years old 
and 10 cases of cardiac function classification were graded 
to grade 30, grade 20 and grade IV.
2.2. Method
Control group is whose only the use of oxygen, salt diet, 
anti-infection and other general support for treatment and 
conventional drug treatment.
On the basis of the control group, treatment group was 
used the treatment of the original disease in order to im-
prove blood flow dynamics and blocking the neuroendo-
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crine abnormalities of the system, according to the prin-
ciple of individual principle of conventional medicine. The 
specific drugs used were: Enalapril (manufacturer: Anhui 
Chinese medicine health Limited by Share Ltd; batch num-
ber: Zhunzi H20083604) 2.5−5.0 mg/times, 2 times a day, 
after gradually increasing the dose of digoxin; (manufac-
turer: Shanghai Xinyi Pharmaceutical Co. Ltd; batch num-
ber: Zhunzi H31020678) 0.25mg/ times, 1 times, daily ex-
cept contraindications; diuretic furosemide (manufacturer: 
Datong Liqun Pharmaceutical Co. Ltd.; batch number: 
Zhunzi H14020358), orally, 20 mg/times, 2−4 times daily; 
spironolactone (manufacturer: Jiangsu Zhengda Feng-
hai Pharmaceutical Co. Ltd; batch number: H32020077) 
10−20 mg/times, 1 times a day; when patients show the 
improvement of symptoms of edema, metoprolol (manu-
facturer: Southwest Pharmaceutical Limited by Share Ltd; 
batch number: H20033191) 6.25−1.5 mg/times, 2 times a 
day. Anticoagulation treatment in the process of general 
oral warfarin (manufacturer: Shanghai Xinyi Pharmaceu-
tical Co., Ltd; batch production: H31022123) is used with 
caution [2].
In the course of treatment, according to the patient’s 
condition changes, the dosage of the drug dosage can be 
adjusted according to the condition.
2.3. Observation index
The two groups of patients with chronic heart failure, the 
effect of treatment, the average recovery time of heart 
function as the observation index for comparison.
2.4. Efficacy evaluation criteria
(1) Excellence: The clinical symptoms and signs of the pa-
tients treated with complete or basic treatment with the 
improvement of cardiac function to achieve or exceed 2 
levels.
(2) Effective: The clinical symptoms and signs of the pa-
tients were significantly relieved, the improvement of car-
diac function reached or exceeded 1, but it was not up to 
grade 2.
(3) Invalid: Clinical symptoms and cardiac function in 
patients treated with no improvement or deterioration.
2.5. Statistical processing
The data obtained in this paper were statistically processed 
using SPSS 15.0 software to carry on the analysis, measure-
ment data using t-test, count data using Chi-Square test, 
when p < 0.05, the difference is statistically significant.
3. Results
3.1. Control effect of two groups of elderly patients
After 1 months of treatment, the treatment group of elder-
ly patients with chronic atrial fibrillation combined with 
heart failure was significantly better than the control group 
and the difference between the two groups was statistically 
significant (p < 0.05). See Table 1.
Table 1. Comparison of the effect of the two groups after 
treatment [cases (%)].
Group
Condition recovery
Excellence Effective Invalid Total effective
Control group 
(n = 60)
15 (25.00) 25 (41.67) 18 (30.00) 42 (70.00)
Treatment 
group (n = 60)
34 (56.67) 20 (33.33) 6 (10.00) 54 (90.00)
χ2 - - - 7.5
p - - - < 0.05
3.2. Average recovery time of heart function
The average recovery time of the treatment group was sig-
nificantly shorter than that in the control group, the differ-
ence between the two groups was obvious, p < 0.05, with 
statistical significance. See Table 2.
Table 2. Comparison of average heart function recovery time 
in two groups of patients.
Group
Average recovery time of heart 
function (d)
Control group (n = 50) 7.76 ± 1.34
Treatment group (n = 50) 4.45 ± 0.88
t 10.25
p < 0.05
4. Conclusion
As the elderly patients with chronic atrial fibrillation and 
heart failure are prone to complicated by various other 
diseases, the treatment is difficult. So for these elderly pa-
tients, the main purpose is to improve their heart function, 
control heart rate, as far as possible by reverse the ventric-
ular remodeling, improve hemodynamics, reduce mortal-
ity, and improve the quality of life. For a short duration of 
patients with 7 real fibrillation drug used, cardioversion ef-
fect is the best. Drug complex is the first choice for patients 
with stable heart function. Although the class I of antiar-
rhythmia drugs is effective in the treatment of atrial fibril-
lation, the case study showed that it can increase mortality, 
so it is not used for the treatment. Calcium antagonists are 
not suitable for the treatment of chronic heart failure with 
atrial fibrillation. Multiple clinical studies (RACE, CHF-
STAT) show that the uses of amiodarone in maintenance of 
sinus rhythm are safe and effective for patient with chronic 
heart failure and atrial fibrillation. A new generation of 
class III antiarrhythmic drug dronedarone cardioversion 
of atrial fibrillation (AF) have a higher rate of success, but 
the ANDROMEDA study show that patients with chronic 
heart failure NYHA class II−IV of dronedaronelevel in-
creased the rate hospitalization due to worsening of heart 
failure and mortality. So it is not recommended for the 
treatment of chronic heart failure patients with atrial fi-
brillation. Besides, sotalol can increase the mortality in 
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patients with heart failure which also should not be used 
for the treatment of patients with heart failure. Dofetilide 
although effective cardioversion of atrial fibrillation in pa-
tients with heart failure, but can increase the occurrence 
of torsade de pointes ventricular tachycardia (TdP) risk. 
It is no longer recommended the use of dofetilide for car-
dioversion and to maintain the sinus rhythm. Therefore, 
for chronic heart failure patients with atrial fibrillation and 
maintenance of sinus rhythm, the amiodarone is currently 
recommended only for patients with chronic heart failure 
patients with repeated episodes of paroxysmal atrial fibril-
lation. But it is necessary to pay attention to the moni-
toring of the toxic effect of amiodarone on the organs. 
Some non-traditional antiarrhythmic drugs through anti-
inflammatory are able to improve the atrial electrical and 
mechanical remodeling as well as improve the heart failure 
of patients with atrial fibrillation and increase the sinus 
rhythm maintenance success rate. Meta-analysis showed 
enalapril, trandolapril, irbesartan, losartan can signifi-
cantly improve patient’s health complicated with chronic 
heart failure and atrial fibrillation patients. Patients who 
are treated with drugs and electrical cardioversion show an 
increase success rate, which may later treated with ACEI/
ARB can reduces cardiac after load, reduce the left atrial 
pressure, wall pressure, improve myocardial remodeling 
and electrical remodeling. But in the other study, lisinopril, 
valsartan, and sill candesartan and showed only for neutral 
results, suggesting that not all ACEI/ARB have such effects. 
Statins can also reduce the incidence of atrial fibrillation in 
patients with heart failure, but the role of the law and the 
maintenance of sinus rhythm are not clear [3].
Chronic heart failure patients with persistent atrial fibril-
lation with the existence of basic heart disease and electri-
cal remodeling, the effect of the drug is often poor after 
the choice of electric power is failed. The used of ablation 
in the atrial fibrillation treatment cannot be transferred to 
the sinus rhythm, but it is feasible for synchronous cardio-
version. For serious symptoms like hemodynamic insta-
bility, or with atrioventricular bypass episode in patients 
with atrial fibrillation, early cardioversion is possible. The 
rate of atrial fibrillation recurrence is high so amiodarone 
in maintaining the rate of sinus rhythm in patients with 
chronic heart failure is required.
Catheter ablation has become one of the important ap-
proaches to the treatment of atrial fibrillation in patients 
with chronic heart failure. Multiple clinical studies have 
shown that catheter ablation of atrial fibrillation with im-
paired systolic function can significantly improve the 6 
minute walking distance, left ventricular ejection fraction, 
improve quality of life, and may reverse ventricular remod-
eling. PABA-CHF is a prospective, multicenter, random-
ized, controlled study showed that compared to the atrio-
ventricular node ablation and dual chamber pacing can 
better improve the cardiac function with heart failure in 
patients with atrial fibrillation catheter ablation; subgroup 
analysis showed that, compared with paroxysmal atrial fi-
brillation and non-paroxysmal atrial fibrillation patients 
from the pulmonary vein isolation benefit (including ejec-
tion fraction and six minutes walking time, quality of life 
(QOL) and left atrial diameter) more. These studies sug-
gest that catheter ablation is safe and effective in patients 
with atrial fibrillation, especially left ventricular ejection 
fraction. Catheter ablation can significantly improve the 
quality of life and may reverse atrial remodeling. The treat-
ment of tachycardia cardiomyopathy can be better than 
the atrioventricular junction ablation plus pacing. Since 
the number of samples is limited and the follow-up time is 
short, the long-term effects need to be further studied, and 
catheter ablation in the treatment of heart failure compli-
cated with atrial fibrillation is recommended as the center 
of experience.
In this study, the control group was treated with con-
ventional therapy and conventional drug therapy, and the 
treatment group was treated with the treatment of the pri-
mary disease, and the treatment of the nervous system. Af-
ter 1 months of treatment, the total effective rate was 90% 
in treatment group and 70% in control group, the average 
recovery time of treatment group was (4.45 + 0.88) day, 
and the recovery time of the control group was (7.76 + 1.34) 
day. The effect of the treatment group was significantly 
higher than that of the control group.
In summary, through observation we can explain that 
with comparison between the two groups of patients 
with chronic atrial fibrillation and heart failure, patient 
of average heart function recovery time with treatment 
effect were able to improve the cardiac function and 
ventricular remodeling. The control of the rhythm of 
the heart by blocking neurosecretory system treatment 
for the elderly patients with chronic atrial fibrillation 
and heart failure patients showed a significant effect. It 
has very important clinical significance and is worth in 
clinical widely used.
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